<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="883">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715243</url>
  </required_header>
  <id_info>
    <org_study_id>SQU-EC/206/2020</org_study_id>
    <nct_id>NCT04715243</nct_id>
  </id_info>
  <brief_title>Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) &amp; Helmet NIV in COVID-19 ARDS Patients</brief_title>
  <acronym>NIV COVID19</acronym>
  <official_title>Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) &amp; Helmet NIV in COVID-19 ARDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sultan Qaboos University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sultan Qaboos University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To determine whether NIV delivered through helmet interface reduces intubation&#xD;
      rate among patients with COVID-19 ARDS compared to face-mask NIV and HFNC.&#xD;
&#xD;
      Design, setting &amp; participants: Two-center randomized clinical trial of 360 patients with&#xD;
      mild to moderate ARDS and confirmed COVID-19 requiring non-invasive ventilation between&#xD;
      August 2020 to January 2021. The patients with respiratory rate (RR) more than 30/min or&#xD;
      oxygen saturation (SpO2) less than 90% or PaO2/FiO2 ratio less than 300 despite standard&#xD;
      oxygen therapy by face mask (&lt;15 L/min) who present to Royal hospital or Sultan Qaboos&#xD;
      University Hospital (SQUH) emergency department, medical wards or intensive care unit (ICU).&#xD;
&#xD;
      Intervention: Patients will be randomly assigned (block randomization) to either face-mask&#xD;
      NIV, HFNC or Helmet NIV. The helmet is a transparent hood that covers the entire head of the&#xD;
      patient and has a rubber collar neck seal.&#xD;
&#xD;
      Main outcome and measures: The primary outcome is the rate of endotracheal intubation at&#xD;
      28-days. Secondary outcomes include hospital mortality at 28 and 90 days, NIV free days,&#xD;
      invasive ventilator free days and hospital length of stay.&#xD;
&#xD;
      Expected results: We assume the failure rate of Helmet NIV to be 30%, failure rate of HFNC to&#xD;
      be 40% and failure rate of face-mask NIV to be 50%. A sample size of 360 patients (120/group)&#xD;
      will achieve a power of 0.90 at a significance level of 0.05. To account for 10% dropout&#xD;
      rate, the total sample required is 396 subjects(132/group).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:&#xD;
&#xD;
        -  &gt; 18 years of age&#xD;
&#xD;
        -  confirmed COVID-19&#xD;
&#xD;
        -  Within 48 hours of presentation in the emergency department, the wards, high dependency&#xD;
           area or intensive care unit (ICU)&#xD;
&#xD;
        -  ARDS according to Berlin definition (P/F &lt; 300) or O2 saturation &lt; 90% or RR &gt; 30/min)&#xD;
           in room air&#xD;
&#xD;
        -  Standard oxygen therapy at flow rate &lt; 15L/min x 60 minutes&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  More than 48 hours of admission&#xD;
&#xD;
        -  Impending cardiopulmonary arrest&#xD;
&#xD;
        -  Need for immediate endotracheal intubation&#xD;
&#xD;
        -  Hemodynamic instability or life-threatening arrhythmias&#xD;
&#xD;
        -  GCS &lt; 8&#xD;
&#xD;
        -  Active intracranial pathology or high ICP&#xD;
&#xD;
        -  Inability to cooperate or protect the airway&#xD;
&#xD;
        -  Pregnancy&#xD;
&#xD;
        -  Tracheostomy&#xD;
&#xD;
        -  DNR or refusing intubation&#xD;
&#xD;
        -  Known type 2 respiratory failure&#xD;
&#xD;
        -  On chronic home oxygen therapy&#xD;
&#xD;
      Enrolment:&#xD;
&#xD;
      Multi-centre randomized trial of confirmed COVID-19 cases presenting to the emergency&#xD;
      department, the ward, high dependency or intensive care unit (ICU) with ARDS requiring&#xD;
      non-invasive mechanical ventilation. It is an open label randomized clinical trial. We will&#xD;
      perform permuted block randomization of 9 and perform concealment.&#xD;
&#xD;
      Consent:&#xD;
&#xD;
      A written consent must be taken from the patient or the decision maker prior to enrollment.&#xD;
&#xD;
      Each of the three arms have pre-specified treatment protocol in the form of algorithm.&#xD;
&#xD;
      For the helmet NIV group, for type 1 respiratory failure (hypoxemia &amp; normal pCO2), CPAP will&#xD;
      be started at 10 cmH2O &amp; FiO2 0.6. Re-assessment will be done every 15-30 minutes and CPAP&#xD;
      and FiO2 will be increased accordinly (CPAP to 15 &amp; FiO2 of 1.0 maximum) If patients develops&#xD;
      hypercapnia, the mode will be changed to BiPAP: IPAP 12-25 cmH2O (max 20) EPAP 8-15 cmH2O.&#xD;
&#xD;
      In the face-mask NIV group, CPAP will be started at 5 cmH2O &amp; FiO2 0.6. Re-assess will be&#xD;
      performed every15-30 minutes. Thereafter CPAP &amp; FiO2 will be adjusted accordingly (maximum&#xD;
      CPAP 12 &amp; FiO2: 1.0) If the patient develops high pCO2 :BiPAP: IPAP 8-20 cmH2O (max 20) EPAP&#xD;
      4-12 cmH2O.&#xD;
&#xD;
      In the high flow nasal cannula group, HFNC will be started at at 20-30 L/min Adjust FiO2 to&#xD;
      keep SpO2 &gt; 92%. Thereafter, it will be titrated to flow to max 60 L/min &amp; FiO2 100%&#xD;
&#xD;
      For all the three groups, these are the following targets:&#xD;
&#xD;
      Target:&#xD;
&#xD;
      SPO2 ≥ 92 % RR ≤ 30/min ROX index &gt; 3.22 (HFNC group) ABG: PaO2/FiO2 &gt;100&#xD;
&#xD;
      If the above targets are not achieved, the ICU team will assess them for possible&#xD;
      endotracheal intubation. In case the patient doesn't tolerate any intervention, they will be&#xD;
      allowed to cross over to the other 2 forms of interventions with intention to treat analysis.&#xD;
&#xD;
      Statistical Analysis:&#xD;
&#xD;
      We tested the null hypothesis that there is no difference between the Helmet-NIV, HFNC and&#xD;
      face-mask-NIV intubation rate and the alternative hypothesis that Helmet NIV and HFNC is&#xD;
      superior to face-mask-NIV. We assumed the failure rate of Helmet NIV to be 30% and the&#xD;
      failure rate of HFNC to be 40% and failure rate of face-mask NIV is 50%. The group subject&#xD;
      counts are allocated 1:1:1. The effect size is 0.12. A sample of 360 subjects, (120/group)&#xD;
      achieves a power of 0.90 at a significance level of 0.05. To account for 10% dropout rate,&#xD;
      the total sample required is 396 subjects(132/group).&#xD;
&#xD;
      Baseline characteristics will be reported by mean and standard deviation for the continuous&#xD;
      variables and numbers and proportions for categorical variables. Intention to treat analysis&#xD;
      to analysis will be used for the results for the primary efficacy point of reduction in the&#xD;
      rate of the intubation between the three groups. Fisher's exact test will be used&#xD;
      between-group differences in the rate of intubation. The face-mask-NIV is considered as a&#xD;
      control group as it is the standard treatment and will calculate t the relative risk and&#xD;
      absolute risk difference for the primary end points. The log-rank test will compare the time&#xD;
      from enrollment to ET intubation for the three groups using Kaplan-Meier curves plot. Similar&#xD;
      analysis will be performed for the 28-day mortality for as the secondary end points. All P&#xD;
      values reported for on primary and secondary end points are based on two-sided tests of 0.05.&#xD;
      The SAS statistical software is used to analyze the data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-centre randomized trial of confirmed COVID-19 cases presenting to the emergency department, the ward, high dependency or intensive care unit (ICU) with ARDS requiring non-invasive mechanical ventilation. They will be assigned to one of the three arms; high flow nasal cannula (HFNC), Face-mask NIV or Helmet NIV.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of endotracheal intubation</measure>
    <time_frame>within the study period with an average of one month.</time_frame>
    <description>The patient will be randomly assigned to one of the treatment arms. Then the patient will be followed up for one month for the primary outcome which is endotracheal intubation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>90 days from the hospital mortality.</time_frame>
    <description>Number of patients who survived compared to who died in each intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Throughout the study completion. An average of 90 days.</time_frame>
    <description>total number of days patients remain in the hospital as inpatient in each intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>Throughout the study completion. An average of 90 days.</time_frame>
    <description>number of days patients remain off intervention (invasive or non-invasive)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Acute Respiratory Distress Syndrome Caused by COVID-19</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Face-mask NIV is the standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High flow nasal cannula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Helmet NIV</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow nasal cannula (HFNC)</intervention_name>
    <description>High flow nasal cannula as a form of non-invasive oxygen delivery</description>
    <arm_group_label>intervention 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Helmet NIV</intervention_name>
    <description>NIV interface</description>
    <arm_group_label>Intervention 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Face-mask NIV</intervention_name>
    <description>NIV interface</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  confirmed COVID-19&#xD;
&#xD;
          -  Within 48 hours of presentation in the emergency department, the wards, high&#xD;
             dependency area or intensive care unit (ICU)&#xD;
&#xD;
          -  ARDS according to Berlin definition (P/F &lt; 300) or O2 saturation &lt; 90% or RR &gt; 30/min)&#xD;
             in room air&#xD;
&#xD;
          -  Standard oxygen therapy at flow rate &lt; 15L/min x 60 minutes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 48 hours of admission&#xD;
&#xD;
          -  Impending cardiopulmonary arrest&#xD;
&#xD;
          -  Need for immediate endotracheal intubation&#xD;
&#xD;
          -  Hemodynamic instability or life-threatening arrhythmias&#xD;
&#xD;
          -  GCS &lt; 8&#xD;
&#xD;
          -  Active intracranial pathology or high ICP&#xD;
&#xD;
          -  Inability to cooperate or protect the airway&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Tracheostomy&#xD;
&#xD;
          -  DNR or refusing intubation&#xD;
&#xD;
          -  Known type 2 respiratory failure&#xD;
&#xD;
          -  On chronic home oxygen therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abdul Hakeem Al Hashim, MD</last_name>
    <phone>96899333350</phone>
    <email>hashim@squ.edu.om</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdullah Al Risi</last_name>
    <email>aalreesi@ymail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sultan Qaboos University Hospital</name>
      <address>
        <city>Muscat</city>
        <zip>123</zip>
        <country>Oman</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdul Hakeem Al Hashim, MD, FRCPC</last_name>
      <phone>96899333350</phone>
      <email>hashim@squ.edu.om</email>
    </contact>
    <contact_backup>
      <last_name>Abdullah Al Risi</last_name>
      <email>aalreesi@ymail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Oman</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 9, 2021</study_first_submitted>
  <study_first_submitted_qc>January 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 23, 2021</last_update_submitted>
  <last_update_submitted_qc>January 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sultan Qaboos University</investigator_affiliation>
    <investigator_full_name>Abdulhakeem Al-Hashim</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publish in a journal</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>after July 2021</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

